Phenytoin alters transcript levels of hormone-sensitive lipase in muscle from horses with hyperkalemic periodic paralysis.
In equine hyperkalemic periodic paralysis (HyperPP), there is evidence suggesting that the primary defect in the sodium channel is associated with a secondary alteration in triacylglycerol-associated fatty acid metabolism (TAFAM) in skeletal muscle. Furthermore, TAFAM may be involved in the therapeutic action of phenytoin. The effects of phenytoin treatment on the transcript levels of three key proteins in TAFAM, hormone sensitive lipase (HSL), carnitine palmitoyltransferase (CPT), and fatty acid binding protein (FABP), were examined. These transcripts were quantitated by competitive reverse transcription polymerase chain reaction in undifferentiated and differentiated primary cultures of equine skeletal muscle from control, heterozygous HyperPP, and homozygous-affected HyperPP horses. There was a 10-fold lower level of HSL transcript in both undifferentiated and differentiated cultures from homozygous-affected horses than from horses of the other genotypes. Phenytoin selectively increased the HSL transcript in homozygous-affected differentiated cultures to levels similar to those of the other genotypes. The levels of CPT and FABP transcripts were unaffected by genotype, differentiation, and phenytoin treatment. These results suggest that the primary defect in HyperPP may secondarily decrease HSL transcript levels and that the therapeutic action of phenytoin may include regulation of mRNA transcripts in skeletal muscle.
Yudkowsky
M L
ML
M.S. 310, Allegheny University of the Health Sciences, Philadelphia, Pennsylvania, 19102-1192, USA.
Beech
J
J
Fletcher
J E
JE
D000818:Animals; D002334:Carnitine O-Palmitoyltransferase / Q000235:genetics / Q000378:metabolism; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D002478:Cells, Cultured; D050556:Fatty Acid-Binding Proteins; D005227:Fatty Acids / Q000378:metabolism; D005838:Genotype; D006734:Horse Diseases / Q000201:enzymology / Q000235:genetics*; D006736:Horses; D006947:Hyperkalemia / Q000201:enzymology / Q000235:genetics* / Q000662:veterinary; D018482:Muscle, Skeletal / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D018996:Myelin P2 Protein / Q000235:genetics / Q000378:metabolism; D009363:Neoplasm Proteins; D010245:Paralyses, Familial Periodic / Q000201:enzymology / Q000235:genetics* / Q000662:veterinary; D010672:Phenytoin / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D015222:Sodium Channels / Q000235:genetics / Q000378:metabolism; D002787:Sterol Esterase / Q000235:genetics*; D014158:Transcription, Genetic / Q000187:drug effects*
D002352:Carrier Proteins; D050556:Fatty Acid-Binding Proteins; D005227:Fatty Acids; D018996:Myelin P2 Protein; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D015222:Sodium Channels; D010672:Phenytoin; D002334:Carnitine O-Palmitoyltransferase; D002787:Sterol Esterase